Small molecule 11β- hydroxysteroid dehydrogenase type 1 inhibitors

Current Topics in Medicinal Chemistry

Volumn 11, Issue 12, 2011, Pages 1464-1475

  Sun, Daqing ^a   Wang, Minghan ^a   Wang, Zhulun ^a  

^a AMGEN INC   (United States)

Author keywords

11 HSD1; 11 HSD2; Amide; Metabolic syndrome; Sulfonamide; Triazole; Type 2 diabetes

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; 2 ANILINOTHIAZOLONE; 3 CHLORO 2 METHYL N [4 [2 (4 METHYL 1 PIPERAZINYL) 2 OXOETHYL] 2 THIAZOLYL]BENZENESULFONAMIDE; AMIDE; ANTIDIABETIC AGENT; BENZAMIDE; BVT 14225; CARBENOXOLONE; CORTISONE; HYDROCORTISONE; OXIDOREDUCTASE INHIBITOR; PF 915275; SULFITE REDUCTASE (NADPH); SULFONAMIDE; SULFONAMIDOOXAZOLE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

BRAIN; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; HYPERGLYCEMIA; IN VIVO STUDY; INSULIN SENSITIVITY; LIVER; LIVER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; REVIEW; SINGLE DRUG DOSE; STREPTOZOCIN DIABETES; STRUCTURE ACTIVITY RELATION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79960013275     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611795860988     Document Type: Review

References (55)

1. Wang, M. The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome. Nutr. Metab., (Lond) 2005, 2, 3.
2. Arnaldi, G.; Angeli, A.; Atkinson, A. B.; Bertagna, X.; Cavagnini, F.; Chrousos, G. P.; Fava, G. A.; Findling, J. W.; Gaillard, R. C.; Grossman, A. B.; Kola, B.; Lacroix, A.; Mancini, T.; Mantero, F.; Newell-Price, J.; Nieman, L. K.; Sonino, N.; Vance, M. L.; Giustina, A.; Boscaro, M. Diagnosis and complications of Cushing's syndrome: a consensus statement. J. Clin. Endocrinol. Metab., 2003, 88, 5593-5602.
3. Faggiano, A.; Pivonello, R.; Spiezia, S.; De Martino, M. C.; Filippella, M.; Di Somma, C.; Lombardi, G.; Colao, A. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J. Clin. Endocrinol. Metab., 2003, 88, 2527-2533.
4. Lamberts, S. W.; Koper, J. W.; De Jong, F. H. The endocrine effects of long-term treatment with mifepristone (RU 486). J. Clin. Endocrinol. Metab., 1991, 73, 187-191.
5. Agarwal, A. K.; Tusie-Luna, M. T.; Monder, C.; White, P. C. Expression of 11 beta-hydroxysteroid dehydrogenase using recombinant vaccinia virus. Mol. Endocrinol., 1990, 4, 1827-1832.
6. Nobel, C. S.; Dunas, F.; Abrahmsen, L. B. Purification of fulllength recombinant human and rat type 1 11beta-hydroxysteroid dehydrogenases with retained oxidoreductase activities. Protein. Expr. Purif., 2002, 26, 349-356.
7. Apostolova, G.; Schweizer, R. A.; Balazs, Z.; Kostadinova, R. M.; Odermatt, A. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue. Am. J. Physiol. Endocrinol. Metab., 2005, 288, E957-964.
8. Jamieson, P. M.; Walker, B. R.; Chapman, K. E.; Andrew, R.; Rossiter, S.; Seckl, J. R. 11beta-hydroxysteroid dehydrogenase type 1 is a predominant 11beta-reductase in the intact perfused rat liver. J. Endocrinol., 2000, 165, 685-692.
9. Schweizer, R. A.; Atanasov, A. G.; Frey, B. M.; Odermatt, A. A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11β-HSD): flavanone selectively inhibits 11β-HSD1 reductase activity. Mol. Cell. Endocrinol., 2003, 212, 41-49.
10. Walker, B. R.; Seckl, J. R. 11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease. Expert Opin. Ther. Targets, 2003, 7, 771-783.
11. Rask, E.; Olsson, T.; Soderberg, S.; Andrew, R.; Livingstone, D. E.; Johnson, O.; Walker, B. R. Tissue-specific dysregulation of cortisol metabolism in human obesity. J. Clin. Endocrinol. Metab., 2001, 86, 1418-1421.
12. Kannisto, K.; Pietilainen, K. H.; Ehrenborg, E.; Rissanen, A.; Kaprio, J.; Hamsten, A.; Yki-Jarvinen, H. Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J. Clin. Endocrinol. Metab., 2004, 89, 4414-4421.
13. Masuzaki, H.; Paterson, J.; Shinyama, H.; Morton, N. M.; Mullins, J. J.; Seckl, J. R.; Flier, J. S. A transgenic model of visceral obesity and the metabolic syndrome. [see comment]. Science, 2001, 294, 2166-2170.
14. Masuzaki, H.; Yamamoto, H.; Kenyon, C. J.; Elmquist, J. K.; Morton, N. M.; Paterson, J. M.; Shinyama, H.; Sharp, M. G.; Fleming, S.; Mullins, J. J.; Seckl, J. R.; Flier, J. S. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest., 2003, 112, 83-90.
15. Kotelevtsev, Y.; Holmes, M. C.; Burchell, A.; Houston, P. M.; Schmoll, D.; Jamieson, P.; Best, R.; Brown, R.; Edwards, C. R.; Seckl, J. R.; Mullins, J. J. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. USA, 1997, 94, 14924-14929.
16. Morton, N. M.; Paterson, J. M.; Masuzaki, H.; Holmes, M. C.; Staels, B.; Fievet, C.; Walker, B. R.; Flier, J. S.; Mullins, J. J.; Seckl, J. R. Novel adipose tissue-mediated resistance to dietinduced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes, 2004, 53, 931-938.
17. Paterson, J. M.; Morton, N. M.; Fievet, C.; Kenyon, C. J.; Holmes, M. C.; Staels, B.; Seckl, J. R.; Mullins, J. J. Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc. Natl. Acad. Sci. USA, 2004, 101, 7088-7093.
18. Kershaw, E. E.; Morton, N. M.; Dhillon, H.; Ramage, L.; Seckl, J. R.; Flier, J. S. Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes, 2005, 54, 1023-1031.
19. Alberts, P.; Engblom, L.; Edling, N.; Forsgren, M.; Klingstrom, G.; Larsson, C.; Ronquist-Nii, Y.; Ohman, B.; Abrahmsen, L. Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia, 2002, 45, 1528-1532.
20. Alberts, P.; Nilsson, C.; Selen, G.; Engblom, L. O.; Edling, N. H.; Norling, S.; Klingstrom, G.; Larsson, C.; Forsgren, M.; Ashkzari, M.; Nilsson, C. E.; Fiedler, M.; Bergqvist, E.; Ohman, B.; Bjorkstrand, E.; Abrahmsen, L. B. Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology, 2003, 144, 4755-4762.
21. Hermanowski-Vosatka, A.; Balkovec, J. M.; Cheng, K.; Chen, H. Y.; Hernandez, M.; Koo, G. C.; Le Grand, C. B.; Li, Z.; Metzger, J. M.; Mundt, S. S.; Noonan, H.; Nunes, C. N.; Olson, S. H.; Pikounis, B.; Ren, N.; Robertson, N.; Schaeffer, J. M.; Shah, K.; Springer, M. S.; Strack, A. M.; Strowski, M.; Wu, K.; Wu, T.; Xiao, J.; Zhang, B. B.; Wright, S. D.; Thieringer, R. 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med., 2005, 202, 517-527.
22. For a review, see the following: Seckl, J. R.; Walker, B. R. Minireview: 11β-Hydroxysteroid dehydrogenase type 1-A tissuespecific amplifier of glucocorticoid action. Endocrinology, 2001, 142, 1371-1376.
23. Stewart, P. M.; Krozowski, Z. S. 11β-Hydroxysteroid dehydrogenase. Vitam. Horm., 1999, 57, 249-324.
24. Barf, T.; Vallgarda, J.; Emond, R.; Haggstrom, C.; Kurz, G.; Nygren, A.; Larwood, V.; Mosialou, E.; Axelsson, K.; Olsson, R.; Engblom, L.; Edling, N.; Ronquist-Nii, Y.; Ohman, B.; Alberts, P.; Abrahmsen, L. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of 11β-hydroxysteroid dehydrogenase type I. J. Med. Chem., 2002, 45, 3813-3815.
25. Xiang, J.; Ipek, M.; Suri, V.; Massefski, W.; Pan, N.; Ge, Y.; Tam, M.; Xing, Y.; Tobin, J. F.; Xu, X.; Tam, S. Synthesis and biological evalution of sulfonamidooxazoles and ε-keto sulfones: selective inhibitors of 11β-hydroxysteroid dehydrogenase type I. Bioorg. Med. Chem. Lett., 2005, 15, 2865-2869.
26. Xiang, J.; Ipek, M.; Suri, V.; Tam, M.; Xing, Y.; Huang, N.; Zhang, Y.; Tobin, J.; Mansour, T. S.; McKew, J. ε-keto sulfones as inhibitors of 11β-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg. Med. Chem. Lett., 2007, 15, 4396-4405.
27. Siu, M.; Johnson, T. O.; Wang, Y.; Nair, S. K.; Taylor, W. D.; Cripps, S. J.; Mattews, J. J.; Edwards, M. P.; Pauly, T. A.; Ermolieff, J.; Castro, A.; Hosea, N. A.; LaPaglia, A.; Fanjul, A. N.; Vogel, J. E. N-(pyridine-2-yl) arylsulfonamide inhibitors of 11β-hydroxysteroid dehydrogenase type I: Discovery of PF-915275. Bioorg. Med. Chem. Lett., 2009, 19, 3493-3497.
28. Bhat, B. G.; Hosa, N.; Fanjul, A.; Herrera, J.; Chapman, J.; Thalacker, F.; Stewart, P. M.; Rejto, P. A. Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11β-hydroxysteroid dehydrogenase type 1, in cynomologus monkeys. J. Pharmacol. Exp. Ther., 2008, 324, 299-305.
29. Zhang, X.; Zhou, Z.; Yang, H.; Chen. J.; Feng, Y.; Du, L.; Leng, Y.; Shen, J. 4-(Phenylsulfonamidomethyl)benzamides as potent and selective inhibitors of 11β-hydroxysteroid dehydrogenase type I with efficacy in diabetic ob/ob mice. Bioorg. Med. Chem. Lett., 2009, 19, 4455-4458.
30. Neelamkavil, S. F.; Boyle, C. D.; Chackalamannil, S.; Greenlee, W. J.; Zhang, L.; Terracina, G. The discovery of azepane sulfonamides as potent 11β-HSD1 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 4563-4565.
31. Xiang, J.; Wan, Z.; Li, H.; Ipek, M.; Binnun, E.; Nunez, J.; Chen, L.; McKew, J. C.; Mansour, T. S.; Xu, X.; Suri, V.; Tam, M.; Xing, Y.; Li, X.; Hahm, S.; Tobin, J.; Saiah, E. Piperazine sulfonamides as potent, selective, and orally available 11β-hydroxysteroid dehydrogenase type I inhibitors with efficacy in the rat cortisoneinduced hyperinsulinemia model. J. Med. Chem., 2008, 51, 4068-4071.
32. Wan, Z.; Chenail, E.; Xiang, J.; Li, H.; Ipek, M.; Bard, J.; Svenson, K.; Mansour, T. S.; Xu, X.; Tian, X.; Suri, V.; Hahm, S.; Xing, Y.; Johnson, C. E.; Li, X.; Qadri, A.; Panza, D.; Perreault, M.; Tobin, J. F.; Saiah, E. Efficacious 11β-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model. J. Med. Chem., 2009, 52, 5449-5461.
33. Sun, D.; Wang, Z.; Di, Y.; Jaen, J. C.; Labelle, M.; Ma, J.; Miao, S.; Sudom, A.; Tang, L.; Tomooka, C. S.; Tu, H.; Ursu, S.; Walker, N.; Yan, X.; Ye, Q.; Powers, J. P. Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Bioorg. Med. Chem. Lett., 2008, 18, 3513-3516.
34. Tu, H.; Powers, J. P.; Liu, J.; Ursu, S.; Sudom, A.; Yan, X.; Xu, H.; Meininger, D.; DeDraffenreid, M.; He, X.; Jaen, J. C.; Sun, D.; Labelle, M.; Yamamoto, H.; Shan, B.; Walker, N.; Wang, Z. Distinctive molecular inhibition mechanisms for selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem., 2008, 16, 8922-8931.
35. Sun, D.; Wang, Z.; Cardozo, M.; Choi, R.; DeGraffenreid, M. R.; Di, Y.; He, X.; Jaen, J. C.; Labelle, M.; Liu, J.; Ma, J.; Miao, S.; Sudom, A.; Tang, L.; Tu, H.; Ursu, S.; Walker, N.; Yan, X.; Ye, Q.; Powers, J. P. Synthesis and optimization of arylsulfonylpiperazines as a novel class of inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Bioorg. Med. Chem. Lett., 2009, 19, 1522-1527.
36. Wang, Z.; Wang, M. Curr. Chem. Biol., 2009, 3, 159-170.
37. Olson, S.; Aster, S. D.; Brown, K.; Carbin, L.; Graham, D. W.; Hermanowski-Vosatka, A.; LeGrand, C. B.; Mundt, S. S.; Robbins, M. A.; Schaeffer, J. M.; Slossberg, L. H.; Szymonifka, M. J.; Thieringer, R.; Wright, S. D.; Balkovec, J. M. Adamantyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem. Lett., 2005, 15, 4359-4362.
38. Aster, S. D.; Graham, D. W.; Kharbanda, D.; Patel, G.; Ponpipom, M.; Santorelli, G. M.; Szymonifka, M. J.; Mundt, S. S.; Shah, K.; Springer, M. S.; Thieringer, R.; Hermoanowski-Vosatka, A.; Wright, S. D.; Xiao, J.; Zokian, H.; Balkovec, J. M. Bis-aryl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem. Lett., 2008, 18, 2799-2804.
39. Gu, X.; Dragovic, J.; Koo, G. C.; Koprak, S. L.; LeGrand, C. B.; Mundt, S. S.; Shah, K.; Springer, M. S.; Tan, E. Y.; Thieringer, R.; Hermanowski-Vosatka, A.; Zokian, H. J.; Balkovec, J. M.; Waddle, S. T. Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11β-HSD1: Novel therapeutic agents for the treatment of metabolic syndrome. Bioorg. Med. Chem. Lett., 2005, 15, 5266-5269.
40. Zhu, Y.; Olson, S. H.; Hermanowski-Vosatka, A.; Mundt, S.; Shah, K.; Springer, M.; Thieringer, R.; Wright, S.; Xiao, J.; Zokian, H.; Balkovec, J. M. 4-Methyl-5-phenyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem. Lett., 2008, 18, 3405-3411.
41. Zhu, Y.; Olson, S. H.; Graham, D.; Patel, G.; Hermanowski-Vosatka, A.; Mundt, S.; Shah, K.; Springer, M.; Thieringer, R.; Wright, S.; Xiao, J.; Zokian, H.; Dragovic, J.; Balkovec, J. M. Phenylcyclobutyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem. Lett., 2008, 18, 3412-3416.
42. Coppola, G. M.; Kukkola, P. J.; Stanton, J. L.; Neubert, A. D.; Marcopulos, N.; Bilci, N. A.; Wang, H.; Tomaselli, H. C.; Tan, J.; Aicher, T. D.; Knorr, D. C.; Jeng, A. Y.; Dardik, B.; Chatelain, R. E. Perhydroquinolylbenzamides as novel inhibitors of 11β-hydroxysteroid dehydrogenase type 1. J. Med. Chem., 2005, 48, 6696-6712.
43. Yeh, V. S. C.; Patel, J. R.; Yong, H.; Kurukulasuriya, R.; Fung, S.; Monzon, K.; Chiou, W.; Wang, J.; Stolarik, D.; Imade, H.; Beno, D.; Brune, M.; Jacobson, P.; Sham, H.; Link, J. T. Synthesis and biological evalution of heterocycle containing adamantine 11β-HSD1 inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 5414-5419.
44. Yeh, V. S. C.; Kurukulasuriya, R.; Madar, D.; Patel, J. R.; Fung, S.; Monzon, K.; Chiou, W.; Wang, J.; Jacobson, P.; Sham, H. L.; Link, J. T. Synthesis and structural activity relationship of 11β-HSD1 inhibitors with novel adamantine replacements. Bioorg. Med. Chem. Lett., 2006, 16, 5408-5413.
45. Sorensen, B.; Winn, M.; Rohde, J.; Shuai, Q.; Wang, J.; Fung, S.; Monzon, K.; Chiou, W.; Stolarik, D.; Imade, H.; Pan, L.; Deng, X.; Chovan, L.; Longenecker, K.; Judge, R.; Qin, W.; Brune, M.; Camp, H.; Frevert, E. U.; Jacobson, P.; Link, J. T. Adamantane sulfone and sulfonamide 11β-HSD1 inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 527-532.
46. Yeh, V. S. C.; Kurukulasuriya, R.; Fung, S.; Monzon, K.; Chiou, W.; Wang, J.; Stolarik, D.; Imade, H.; Shapiro, R.; Knourek-Segel, V.; Bush, E.; Wilcox, D.; Nguyen, P. T.; Brune, M.; Jacobson, P.; Link, J. T. Discovery of orally active butyrolactam 11β-HSD1 inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 5555-5560.
47. Julian, L. D.; Wang, Z.; Bostick, T.; Caille, S.; Choi, R.; DeGraffenreid, M.; Di, Y.; He, X.; Hungate, R. W.; Jaen, J. C.; Liu, J.; Monshouwer, M.; McMinn, D.; Rew, Y.; Sudom, A.; Sun, D.; Tu, H.; Ursu, S.; Walker, N.; Yan, X.; Ye, Q.; Powers, J. P. Discovery of novel, potent benzamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model. J. Med. Chem., 2008, 51, 3953-3960.
48. McMinn, D. L.; Rew, Y.; Sudom, A.; Caille, S.; DeGraffenreid, M.; He, X.; Hungate, R. W.; Jiang, B.; Jaen, J. C.; Julian, L. D.; Kaizerman, J.; Novak, P.; Sun, D.; Tu, H.; Ursu, S.; Walker, N. P. C.; Yan, X.; Ye, Q.; Wang, Z.; Powers, J. P. Optimization of novel di-substituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 1446-1450.
49. Rew, Y.; McMinn, D. L.; Wang, Z.; He, X.; Hungate, R. W; Jaen, J. C.; Sudom, A.; Sun, D.; Tu, H.; Ursu, S.; Villemure, E.; Walker, N. P. C.; Yan, X.; Ye, Q.; Powers, J. P. Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11β-HSD1 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 1797-1801.
50. Sun, D.; Wang, Z.; Caille, S.; DeGraffenreid, M.; Gonzalez-Lopez de Turiso, F.; Hungate, R.; Juan, C.; Jaen, J. C.; Jiang, B.; Julian, L. D.; Kelly, R.; McMinn, D.; Kaizerman, J.; Rew, Y.; Sudom, A.; Tu, H.; Ursu, S.; Walker, N.; Willcockson, M.; Yan, X.; Ye, Q.; Powers, J. P. Synthesis and Optimization of Novel 4,4-Disubstituted Cyclohexylbenzamide Derivatives as Potent 11β-HSD1 Inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(1), 405-410.
51. Yuan, C.; St. Jean, D. J.; Liu, Q.; Cai, L.; Li, A.; Han, N.; Moniz, G.; Askew, B.; Hungate, R. W.; Johansson, L.; Tedenborg, L.; Pyring, D.; Williams, M.; Hale, C.; Chen, M.; Cupples, R.; Zhang, M.; Jordan, S.; Bartberger, M. D.; Sun, Y.; Emery, M.; Wang, M.; Fotsch, C. The discovery of 2-anilinothiazoles as 11β-HSD1 inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 6056-6061.
52. Johansson, L.; Fotsch, C.; Bartberger, M. D.; Castro, V. M.; Chen, M.; Emery, M.; Gustafsson, S.; Hale, C.; Hickman, D.; Homan, E.; Jordan, S. R.; Komorowski, R.; Li, A.; McEae, K.; Moniz, G.; Matsumoto, G.; Orihuela, C.; Palm, G.; Veniant, M.; Wang, M.; Williams, M.; Zhang, J. 2-Amino-1,3-thiazol-4(5H)-ones as potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitors: Enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57B1/6 mice. J. Med. Chem., 2008, 51, 2933-2943.
53. St. Jean, D. J.; Jr.; Yuan, C.; Bercot, E. A.; Cupples, R.; Chen, M.; Fretland, J.; Hale, C.; Hungate, R. W.; Komorowski, R.; Veniant, M.; Wang, M.; Zhang, X.; Fotsch, C. 2-(S)-Phenethylaminothiazolones as potent, orally efficacious inhibitors of 11β-hydroxysteroid dehydrogenase type 1. J. Med. Chem., 2007, 50, 429-432.
54. Incyte Corporation. Presented at UBS Global Life Sciences Conference, 2007.
55. th Annual JPMorgan Healthcare Conference, 2007.